RhoVac publishes research results prior ASCO's meeting
RhoVac announces today, 21st May 2019, that a summary of the collaboration with Lund University has been published prior to the upcoming ASCO Annual Meeting (American Society of Clinical Oncology) held in Chicago on May 31-June 4.
The primary objective of the study was to investigate whether RhoC is expressed to a greater extent in cancer stem cells in prostate cancer induced metastases in radiation exposed mice. The metastasis tissues were harvested, sectioned and analyzed by immunohistochemical methods, comparing the presence of different biomarkers. The biomarkers analyzed were for RhoC, Adenoreceptor (AR), CD 166 (cancer stem cell) and Ki67 (proliferation). The results showed, that RhoC is expressed to a greater extent in the metastatic tissue and, and that there is a subpopulation of RhoC-positive cells in the metastases, which are double-labeled with CD166 to the cancer stem cells.
Anders Ljungqvist, CEO: - It was satisfying to see that these results confirmed that RhoC was expressed to a greater extent in the metastasis tissue than in the tumor, and that a subpopulation of the RhoC-positive cells also has cancer stem cell character.
Abstract is available at ASCO homepage: http://www.abstract.asco.org/239/AbstView_239_268065.html
For more information, please contact:
Anders Ljungqvist – VD, RhoVac AB
Phone: +45 4083 2365
This is an English version of an original Swedish press release communicated by RhoVac AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that RhoVac AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 21st May 2019
About RhoVac AB
RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's top-line results from the clinical phase I / II study has been published I August 2018. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on Spotlight Trade Market, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com.